# Zymeworks

Source: https://onco.cc/companies/zymeworks/  
OnCo record `zymeworks` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zymeworks invented zanidatamab and a hydrophilic TOP1 ADC platform (ZW191 FRα, ZW251 GPC3).

## Summary

Zymeworks, based in Vancouver and listed as ZYME, invented zanidatamab, the HER2 bispecific antibody, and a hydrophilic topoisomerase 1 ADC platform. Its Azymetric platform produced zanidatamab, on which it earns royalties, and its own pipeline includes ZW191, a folate receptor alpha ADC that reported a 52 percent response rate in pretreated ovarian and endometrial cancer at AACR 2026, and ZW251 against GPC3. In September 2026 Zymeworks completed its acquisition of Theravance Biopharma, a company outside oncology, for 17 dollars a share in cash plus a contingent value right tied to ampreloxetine, and in October 2026 it licensed worldwide rights to ZW209, a trispecific T-cell engager against DLL3, to Roche for 55 million dollars upfront, a deal awaiting US antitrust clearance. OnCo links it to biliary tract cancer and HER2-positive breast cancer, to the zanidatamab drug record and to Zai Lab. Whether its second-generation ADCs can repeat the success of a bispecific it no longer controls is the open question. Zanidatamab has its own page.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Vancouver
- Type: biotech
- Website: https://www.zymeworks.com
- Ticker: ZYME

## Notes

- Freshened 29 October 2026 from Zymeworks SEC 8-K filings: the Theravance merger agreement (28 June 2026) and completion (23 September 2026), and the Roche collaboration and licence agreement (22 October 2026), which takes effect after Hart-Scott-Rodino clearance. No acquisition of Zymeworks was found.

## Sources

- Official website: https://www.zymeworks.com
- Theravance acquisition completed (SEC 8-K, September 2026): https://www.sec.gov/Archives/edgar/data/1937653/000119312526399383/d270232d8k.htm
- Roche licence for ZW209 (SEC 8-K, October 2026): https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/zyme-20261022.htm

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [Zanidatamab zovodotin](https://onco.cc/drugs/zanidatamab-zovodotin/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- trials: [HERIZON-BTC-01](https://onco.cc/trials/herizon-btc-01/), [HERIZON-BTC-302](https://onco.cc/trials/herizon-btc-302/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)
- key papers: [Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study](https://onco.cc/key-papers/paper-harding-lancet-oncol/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/zymeworks.json